MANAGEMENT OF PATIENTS WITH HEMOPHILIA A ON EMICIZUMAB PROPHYLACTIC TREATMENT: RECOMMENDATION FROM RUSSIAN EXPERTS

被引：0

作者：

Andreeva, T. A. ^{[1
]}

Zharkov, P. A. ^{[3
]}

Zozulya, N., I ^{[4
]}

Zorenko, V. Yu ^{[4
]}

Konstantinova, V. N. ^{[1
]}

Lebedev, V. V. ^{[2
]}

Mamaev, A. N. ^{[5
]}

Markova, I., V ^{[6
]}

Petrov, V. Yu ^{[7
]}

Polyanskaya, T. Yu ^{[8
]}

Schiller, E. E. ^{[9
]}

机构：

[1] Hematologist Head City Ctr Treatment Patients, City Polyclin 37, St Petersburg 191186, Russia

[2] Childrens Reg Clin Hosp, Head Childrens Reg Oncohematol Ctr, Minist Hlth Krasnodar Reg, Krasnodar 350007, Russia

[3] Dmitriy Rogachev Natl Med Res Ctr Pediat Hematol, Hematologist Consultat Dept, Pediatrician Short Term Treatment Inpatient Dept, Moscow 117997, Russia

[4] Natl Med Res Ctr Hematol, Head Dept Hemostasis Disorders, Moscow 125167, Russia

[5] Natl Med Res Ctr Hematol, Altai Div, Minist Hlth Russian Federat, Moscow 125167, Russia

[6] Raisa Gorbacheva Mem Res Inst Pediat Oncol Hemato, St Petersburg 1999022, Russia

[7] Morozovskaya Childrens City Clin Hosp, Moscow Hlth Dept, Hematologist Hematol Dept, Moscow 119049, Russia

[8] Natl Res Ctr Hematol, Dept Traumatol & Orthoped, Moscow 125167, Russia

[9] Odintsovo Reg Hosp, Head Children Hematol Dept, Odintsovo 143003, Russia

来源：

GEMATOLOGIYA I TRANSFUZIOLOGIYA | 2022年 / 67卷 / 02期

关键词：

emicizumab; hemophilia; factor VIII; factor VIII inhibitor; BISPECIFIC ANTIBODY; INHIBITORS; BLEEDS;

D O I：

10.35754/0234-5730-2022-67-2-267-280

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction. In 2018 emicizumab was approved in Russia for prophylactic treatment in patients with hemophilia A (HA) with inhibitors and in 2019 for patients with severe HA without inhibitors. A significant amount of data has been accumulated from clinical trials and real-world data, which allow us to resolve most of the questions that hematologists may have when to prescribe emicizumab. Aim - to provide information on the management of patients on emicizumab. Results. The recommendations accumulated the currently available information and world experience in the management of patients receiving emicizumab in order to facilitate decision-making when prescribing and using emicizumab. Information on the use of emicizumab in patients with HA with FVIII inhibitors and severe HA without FVIII inhibitors is presented. Possible complications and measures for their prevention and treatment are presented.

引用

页码：267 / 280

页数：14

共 48 条

[1] Challenges in prophylactic therapy with Emicizumab in patients with hemophilia A: Focus on monitoring tests
Brinza, Melen
Uscatescu, Valentina
Hemcinschi, Mihai
Chiriac, Elisabeta
Gherghe, Georgiana
Coriu, Daniel
REVISTA ROMANA DE MEDICINA DE LABORATOR, 2024, 32 (01): : 93 - 100
[2] Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab
Jimenez-Yuste, Victor
Alvarez-Roman, Maria A.
Berrueco, Ruben
Bonanad, Santiago
Calvo-Villas, Jose M.
Gonzalez-Gonzalez, Rebeca
Gonzalez Porras, Jose R.
J. Nunez-Vazquez, Ramiro
Rodriguez-Lopez, Manuel
TH OPEN, 2024, 08 (02) : e194 - e201
[3] Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
Cohen, Omri
Levy-Mendelovich, Sarina
Budnik, Ivan
Ludan, Noa
Lyskov, Shani Kassia
Livnat, Tami
Avishai, Einat
Efros, Orly
Lubetsky, Aharon
Lalezari, Shadan
Misgav, Mudi
Brutman-Barazani, Tami
Kenet, Gili
Barg, Assaf A.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (06)
[4] Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab
Bou-Jaoudeh, Melissa
Mimoun, Angelina
Delignat, Sandrine
Peyron, Ivan
Capdevila, Ladislas
Daventure, Victoria
Deligne, Claire
Dimitrov, Jordan D.
Christophe, Olivier D.
Denis, Cecile V.
Lenting, Peter J.
Proulle, Valerie
Lacroix-Desmazes, Sebastien
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (10) : 2776 - 2783
[5] Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
Escobar, Miguel
Agrawal, Neha
Chatterjee, Sagnik
Bhattacharya, Swastik
Caicedo, Jorge
Bullano, Michael
Schultz, Bob G. G.
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 574 - 580
[6] Limitations of prophylactic treatment in patients with hemophilia
Lopez Fernandez, Maria Fernanda
BLOOD COAGULATION & FIBRINOLYSIS, 2019, 30 : S22 - S24
[7] Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A
Takeyama, Masahiro
Matsumoto, Naoki
Abe, Hiroto
Harada, Suguru
Ogiwara, Kenichi
Furukawa, Shoko
Shimonishi, Naruto
Nakajima, Yuto
Yada, Koji
Soeda, Tetsuhiro
Nogami, Keiji
PEDIATRIC BLOOD & CANCER, 2023, 70 (10)
[8] Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada
Yu, Jacky K. K.
Wong, William W. L.
Keepanasseril, Arun
Iorio, Alfonso
Edginton, Andrea N. N.
HAEMOPHILIA, 2023, 29 (02) : 488 - 497
[9] Budgetary impact of emicizumab versus activated prothrombin complex concentrate (aPCC) for the prophylactic treatment of hemophilia A with inhibitors
Dongo, Victor
REVISTA DEL CUERPO MEDICO DEL HOSPITAL NACIONAL ALMANZOR AGUINAGA ASENJO, 2023, 16 (03):
[10] Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions
Yaoi, Hiroaki
Shida, Yasuaki
Kitazawa, Takehisa
Shima, Midori
Nogami, Keiji
THROMBOSIS AND HAEMOSTASIS, 2021, 121 (03) : 279 - 286

← 1 2 3 4 5 →